AstraZeneca to manufacture ADCs in Singapore
20 May 2024 AstraZeneca plans $1.5 billion manufacturing facilityfor antibody drug conjugates (ADCs) in Singapore Operationally ready by 2029, it will be the Company'sfirst-ever facility to cover the full manufacturing process for ADCs AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. The planned greenfield facility, supported